726 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Capital Investment Advisors LLC

Capital Investment Advisors LLC bought a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 726 shares of the pharmaceutical company’s stock, valued at approximately $205,000.

Several other large investors also recently modified their holdings of VRTX. Norges Bank bought a new stake in Vertex Pharmaceuticals during the 4th quarter valued at approximately $588,506,000. Wellington Management Group LLP boosted its position in Vertex Pharmaceuticals by 23.6% during the 1st quarter. Wellington Management Group LLP now owns 8,053,710 shares of the pharmaceutical company’s stock valued at $2,101,776,000 after acquiring an additional 1,535,255 shares in the last quarter. Alliancebernstein L.P. boosted its position in Vertex Pharmaceuticals by 15.2% during the 4th quarter. Alliancebernstein L.P. now owns 10,443,771 shares of the pharmaceutical company’s stock valued at $2,293,452,000 after acquiring an additional 1,374,923 shares in the last quarter. Capital World Investors boosted its position in Vertex Pharmaceuticals by 9.9% during the 1st quarter. Capital World Investors now owns 12,666,130 shares of the pharmaceutical company’s stock valued at $3,305,417,000 after acquiring an additional 1,145,275 shares in the last quarter. Finally, Lord Abbett & CO. LLC bought a new stake in Vertex Pharmaceuticals during the 1st quarter valued at approximately $167,910,000. 91.33% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Sangeeta N. Bhatia sold 621 shares of the company’s stock in a transaction on Friday, July 29th. The shares were sold at an average price of $278.77, for a total value of $173,116.17. Following the completion of the transaction, the director now owns 5,282 shares of the company’s stock, valued at approximately $1,472,463.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Vertex Pharmaceuticals news, CEO Reshma Kewalramani sold 11,689 shares of the stock in a transaction dated Friday, June 24th. The shares were sold at an average price of $291.30, for a total transaction of $3,405,005.70. Following the completion of the transaction, the chief executive officer now owns 111,153 shares of the company’s stock, valued at approximately $32,378,868.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sangeeta N. Bhatia sold 621 shares of the stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $278.77, for a total transaction of $173,116.17. Following the transaction, the director now directly owns 5,282 shares of the company’s stock, valued at approximately $1,472,463.14. The disclosure for this sale can be found here. In the last quarter, insiders sold 208,520 shares of company stock valued at $59,937,985. Company insiders own 0.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Cowen boosted their price target on Vertex Pharmaceuticals from $305.00 to $310.00 and gave the stock an “outperform” rating in a research report on Monday, June 13th. Cantor Fitzgerald began coverage on Vertex Pharmaceuticals in a research report on Tuesday, July 12th. They issued an “overweight” rating and a $365.00 price target on the stock. Maxim Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $325.00 price objective for the company in a report on Wednesday, June 1st. HC Wainwright boosted their price objective on shares of Vertex Pharmaceuticals from $275.00 to $300.00 and gave the stock a “buy” rating in a report on Friday, August 5th. Finally, SVB Leerink began coverage on shares of Vertex Pharmaceuticals in a report on Monday, May 23rd. They issued a “market perform” rating and a $265.00 price objective for the company. Six analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $291.65.

Vertex Pharmaceuticals Trading Down 1.6 %

NASDAQ:VRTX opened at $285.14 on Tuesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.50 and a quick ratio of 4.36. The firm has a market capitalization of $73.13 billion, a price-to-earnings ratio of 23.05, a price-to-earnings-growth ratio of 2.07 and a beta of 0.45. Vertex Pharmaceuticals Incorporated has a one year low of $176.36 and a one year high of $305.95. The business has a fifty day moving average price of $287.61 and a 200-day moving average price of $272.60.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Rating) last posted its quarterly earnings data on Thursday, August 4th. The pharmaceutical company reported $3.60 EPS for the quarter, topping the consensus estimate of $3.12 by $0.48. The firm had revenue of $2.20 billion during the quarter, compared to analyst estimates of $2.13 billion. Vertex Pharmaceuticals had a return on equity of 31.22% and a net margin of 38.26%. Vertex Pharmaceuticals’s revenue was up 22.5% on a year-over-year basis. During the same period in the prior year, the business posted $2.80 EPS. Sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 12.56 EPS for the current year.

About Vertex Pharmaceuticals

(Get Rating)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Featured Stories

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.